Burley SK, Berman HM, Duarte JM, Feng Z, Flatt JW, Hudson BP, Lowe R, Peisach E, Piehl DW, Rose Y, Sali A, Sekharan M, Shao C, Vallat B, Voigt M, Westbrook JD, Young JY, Zardecki C (2022) Protein data bank: a comprehensive review of 3D structure holdings and worldwide utilization by researchers, educators, and students. Biomolecules. https://doi.org/10.3390/biom12101425

Article  PubMed  PubMed Central  Google Scholar 

Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inform Model 61(8):3891–3898. https://doi.org/10.1021/acs.jcim.1c00203

Article  CAS  Google Scholar 

Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogné J-M (2018) BCR-ABL tyrosine kinase inhibitors: which mechanism(s) may explain the risk of thrombosis? TH Open 02(01):e68–e88. https://doi.org/10.1055/s-0038-1624566

Article  Google Scholar 

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C (2017) Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:41–51. https://doi.org/10.1093/annonc/mdx219

Article  Google Scholar 

How do cancer cells grow and spread? - InformedHealth.org - NCBI Bookshelf. (n.d.). Retrieved 13 July 2023, from https://www.ncbi.nlm.nih.gov/books/NBK279410/?report=printable

Jakubec D, Skoda P, Krivak R, Novotny M, Hoksza D (2022) PrankWeb 3: accelerated ligand-binding site predictions for experimental and modelled protein structures. Nucl Acids Res 50(W1):W593–W597. https://doi.org/10.1093/nar/gkac389

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA (2011) Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac Oncol 6(6):1128–1131. https://doi.org/10.1097/JTO.0b013e3182161508

Article  PubMed  PubMed Central  Google Scholar 

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Hassabis D (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596(7873):583–589. https://doi.org/10.1038/s41586-021-03819-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L (2023) Global burden and trends of lung cancer incidence and mortality. Chin Med J 136(13):1583–1590. https://doi.org/10.1097/CM9.0000000000002529

Article  PubMed  PubMed Central  Google Scholar 

Lindauer M, Hochhaus A (2010) Dasatinib. In: Martens UM (ed) Recent results in cancer research. Springer, Berlin

Google Scholar 

Nallanthighal S, Heiserman JP, Cheon DJ (2021) Collagen type xi alpha 1 (Col11a1): a novel biomarker and a key player in cancer. Cancers 13(5):1–22. https://doi.org/10.3390/cancers13050935

Article  CAS  Google Scholar 

Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Can Res 65(20):9185–9189. https://doi.org/10.1158/0008-5472.CAN-05-1731

Article  CAS  Google Scholar 

O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open babel: an open chemical toolbox. J Cheminform. https://doi.org/10.1186/1758-2946-3-33

Article  PubMed  PubMed Central  Google Scholar 

Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE (2021) UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci 30(1):70–82. https://doi.org/10.1002/pro.3943

Article  CAS  PubMed  Google Scholar 

Poy D, Ebrahimi Shahemabadi H, Akbarzadeh A, Moradi-Sardareh H, Ebrahimifar M (2018) Carboplatin liposomal nanoparticles: preparation, characterization, and cytotoxicity effects on lung cancer in vitro environment. Int J Polym Mater Polym Biomater 67(6):367–370. https://doi.org/10.1080/00914037.2017.1332624

Article  CAS  Google Scholar 

Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT (2014) Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm 474(1–2):112–122. https://doi.org/10.1016/j.ijpharm.2014.08.019

Article  CAS  PubMed  Google Scholar 

Scher KS, Somlo G (2013) Dasatinib: a novel therapy for breast cancer? Expert Opin Investig Drugs 22(6):795–801. https://doi.org/10.1517/13543784.2013.793308

Article  CAS  PubMed  Google Scholar 

Shen L, Yang M, Lin Q, Zhang Z, Zhu B, Miao C (2016) COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep 36(2):877–885. https://doi.org/10.3892/or.2016.4869

Article  CAS  PubMed  Google Scholar 

Sun Y, Liu Z, Huang L, Shang Y (2021) MiR-144-3p inhibits the proliferation, migration and invasion of lung adenocargen cancer cells by targeting COL11A1. J Chemother 33(6):409–419. https://doi.org/10.1080/1120009X.2021.1906031

Article  CAS  PubMed  Google Scholar 

Torres-Martinez Z, Delgado Y, Ferrer-Acosta Y, Suarez-Arroyo IJ, Joaquín-Ovalle FM, Delinois LJ, Griebenow K (2021) Key genes and drug delivery systems to improve the efficiency of chemotherapy. Cancer Drug Resist 4(1):163–191. https://doi.org/10.2051/cdr.2020.64

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsoukalas N, Aravantinou-Fatorou E, Tolia M, Giaginis C, Galanopoulos M, Kiakou M, Kostakis ID, Dana E, Vamvakaris I, Korogiannos A, Tsiambas E, Salemis N, Kyrgias G, Karameris A, Theocharis S (2017) Epithelial-mesenchymal transition in non small-cell lung cancer. Anticancer Res 37(4):1773–1778. https://doi.org/10.2187/anticanres.11510

Article  CAS  PubMed  Google Scholar 

Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL (2015) In vitro dissolution methodology, mini-gastrointestinal simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. Eur J Pharm Sci 76:203–212. https://doi.org/10.1016/j.ejps.2015.05.013

Article  CAS  PubMed  Google Scholar 

Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, Zídek A, Green T, Tunyasuvunakool K, Petersen S, Jumper J, Clancy E, Green R, Vora A, Lutfi M, Velankar S (2022) AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucl Acids Res 50(D1):D439–D444. https://doi.org/10.1093/nar/gkab1061

Article  CAS  PubMed  Google Scholar 

Wang M, Yuang A, Chang C (2018) Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells. Oncotarget. https://doi.org/10.1863/oncotarget.24814

Article  PubMed  PubMed Central  Google Scholar 

Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129–138. https://doi.org/10.1038/nrd2742

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu YH, Chou CY (2022) Collagen XI alpha 1 chain, a novel therapeutic target for cancer treatment. Front Oncol. https://doi.org/10.3389/fonc.2022.925165

Article  PubMed  PubMed Central  Google Scholar 

Yoon YI, Kwon Y-S, Cho H-S, Heo S-H, Park KS, Park SG, Lee S-H, Hwang SI, Kim YI, Jae HJ, Ahn G-J, Cho Y-S, Lee H, Lee HJ, Yoon T-J (2014) Ultrasound-mediated gene and drug delivery using a microbubble-liposome particle system. Theranostics 4(11):1133–1144. https://doi.org/10.7150/thno.9945

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M, Tian J, Wang R, Song M, Zhao R, Chen H, Liu K, Shim JH, Zhu F, Dong Z, Lee MH (2020) Dasatinib inhibits lung cancer cell growth and patient derived tumor growth in mice by targeting LIMK1. Front Cell Dev Biol. https://doi.org/10.3389/fcell.2020.556532

Article  PubMed  PubMed Central